Den 12 maj 2025 meddelade AcuCort (”AcuCort” eller ”Bolaget”) att Bolaget mottagit en ny order på Ze...
ByggPartnerGruppen levererade en stark rapport där orderingången närapå dubblades.
Redeye notes that Smart Eye’s Q1 reflected mixed performance due to weaker than expected sales in bo...
Relais reported Q1 adjusted EBITA of EUR 9.2m was down 5% y/y, in line with LSEG Data & Analytics co...
Net sales of SEK67.7m were almost SEK9m higher than expected.
Net sales and EBITDA without insurance compensation were broadly in line with our expectations for Q...
Q1 likely solid, Q2 comments on activity in focus We expect FY guidance to be reiterated EBITA -3-4%...
Stabilt, stabilare, EQL Pharma Nettoomsättningen ökade med imponerande 45,0 %, främst drivet av tidi...
Redeye provides a brief comment following Alzinova’s announcement of the outcome of its SEK35.
Redeye strengthens its positive view of CombinedX after acquiring the IFS partner Align.
Redeye thinks the new positive MAD results from CAN10 further support the case.
Redeye provides its initial view on Kontigo Care’s Q1 2025 results, which came in slightly below exp...
Redeye returns with a more in-depth take on the Q1 report.
Digging into the feasibility study and mineral resource update Feasibility study arrives an NPV of S...
Redeye provides a research update following IRLAB's Q1 report.
